|Mr. Jeffrey S. Hackman||Chairman, President & CEO||400k||N/A||1960|
|Mr. Michael G. Campbell CPA||Executive VP & CFO||269.11k||N/A||1969|
|Dr. David Soane Ph.D.||Co-Founder & Member of Scientific Advisory Board||N/A||N/A||N/A|
|Dr. Robert P. Mahoney Ph.D.||Chief Scientific Officer||292.12k||N/A||1964|
|Ms. Janice Marie McCourt B.S., CLP, M.B.A., R.Ph.||Chief Business Officer||N/A||N/A||1962|
Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.
Comera Life Sciences Holdings, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.